Study Details
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects from 3 to Less than 12 Years of Age with Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
Clinicaltrials.gov ID
Astellas Study ID
178-CL-203
EudraCT ID
2015-000700-26
Condition
Overactive Bladder Disease, Bladder Disease
Phase
Phase 1
Age
3 years - 11 years
Sex
Female & Male
Product
mirabegron + solifenacin succinate
Type
Interventional
Trial Dates
Dec 2015 - Sep 2016
Masking
None (Open Label)
Enrollment number
9
A Multicentre, Open-Label, Single Dose, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects from 3 to Less than 12 Years of Age with Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects from 3 to Less than 12 Years of Age with Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site PL48001
Warsaw, Poland, 04-730
Site DK45002
Aalborg, Denmark, 9000
Site DK45001
Aarhus, Denmark, 8200